Efficacy and Safety of Gonadotropin-Releasing Hormone Agonist Treatment to Suppress Puberty in Gender Dysphoric Adolescents

doi:10.1016/j.jsxm.2016.05.004

The Journal of Sexual Medicine

Volume 13, Issue 7, July 2016, Pages 1125-1132

https://doi.org/10.1016/j.jsxm.2016.05.004 Get rights and content

Abstract

Introduction

Puberty suppression using gonadotropin-releasing hormone agonists (GnRHas) is recommended by current guidelines as the treatment of choice for gender dysphoric adolescents. Although GnRHas have long been used to treat precocious puberty, there are few data on the efficacy and safety in gender dysphoric adolescents. Therefore, the Endocrine Society guideline recommends frequent monitoring of gonadotropins, sex steroids, and renal and liver function.

Aim

To evaluate the efficacy and safety of GnRHa treatment to suppress puberty in gender dysphoric adolescents.

Methods

Forty-nine male-to-female and 67 female-to-male gender dysphoric adolescents treated with triptorelin were included in the analysis.

Main Outcome Measures

Physical examination, including assessment of Tanner stage, took place every 3 months and blood samples were drawn at 0, 3, and 6 months and then every 6 months. Body composition was evaluated using dual energy x-ray absorptiometry.

Results

GnRHa treatment caused a decrease in testicular volume in 43 of 49 male-to-female subjects. In one of four female-to-male subjects who presented at Tanner breast stage 2, breast development completely regressed. Gonadotropins and sex steroid levels were suppressed within 3 months. Treatment did not have to be adjusted because of insufficient suppression in any subject. No sustained abnormalities of liver enzymes or creatinine were encountered. Alkaline phosphatase decreased, probably related to a slower growth velocity, because height SD score decreased in boys and girls. Lean body mass percentage significantly decreased during the first year of treatment in girls and boys, whereas fat percentage significantly increased.

Conclusion

Triptorelin effectively suppresses puberty in gender dysphoric adolescents. These data suggest routine monitoring of gonadotropins, sex steroids, creatinine, and liver function is not necessary during treatment with triptorelin. Further studies should evaluate the extent to which changes in height SD score and body composition that occur during GnRHa treatment can be reversed during subsequent cross-sex hormone treatment.

Introduction

Gender dysphoria is characterized by incongruence between the experienced gender and the sex assigned at birth. It was believed to be a rare phenomenon, but the number of individuals seeking advice and/or treatment at dedicated clinics is increasing.¹ Children can express a sense of belonging to the other sex at a very young age and might show gender role behavior typical of the experienced gender. However, studies have shown that in the children who met the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision criteria for gender identity disorder, the gender dysphoria persisted into adolescence only in a minority.² If gender dysphoria persists or worsens at the onset of puberty, then it is very likely that it will persist into adulthood.²

The Endocrine Society has issued a clinical practice guideline on the endocrine treatment of gender dysphoric individuals.³ For adolescents, pubertal development of the natal sex can be very distressing. Once irreversible characteristics of the natal sex have developed, such as breasts in natal girls and a low voice and outgrowth of the Adam's apple and jaw in natal boys, it becomes more difficult for the individual to live in the experienced gender. Therefore, treatment with gonadotropin-releasing hormone agonists (GnRHas) to suppress puberty is recommended. This gives individuals time to carefully consider their wishes regarding gender-affirming treatment without the distress caused by the development of unwanted sex characteristics. From approximately 16 years of age, individuals can be treated with sex steroids to induce the sex characteristics consistent with the gender identity.³

Treatment with GnRHa has been shown to improve psychological well-being in several domains.⁴ However, physical outcome has not been very well studied. The Endocrine Society guidelines describe that testicular volume decreases and slight development of sex characteristic regresses,³ but little evidence is available to support these statements.⁵ This makes it difficult to counsel individuals on what they can expect. In addition, it is recommended to measure gonadotropins and sex steroids every 3 months during treatment and monitor liver enzymes and renal function.³ However, the necessity of these frequent measurements is uncertain. A consensus statement on the use of GnRHa in children states there is insufficient evidence for any specific short-term monitoring scheme.⁶ GnRHas have been used for many years for the treatment of children with precocious puberty and no side effects on liver or kidney function have been reported, but adolescents might respond differently.

Section snippets

Aim

We set out to describe the changes in Tanner stage, testicular volume, gonadotropins, and sex steroids during GnRHa treatment of gender dysphoric adolescents to evaluate the efficacy of this treatment. In addition, we report on the yield of monitoring liver enzymes and renal function and on changes in body composition.

Subjects and Protocol

Gender dysphoric adolescents seen at the Centre of Expertise on Gender Dysphoria at the VU University Medical Centre (Amsterdam Netherlands) from 1998 through 2009 were invited to participate in a study on brain development, brain functioning, growth, and metabolic aspects of their treatment. These adolescents were diagnosed as described in existing guidelines,³ were eligible for treatment fulfilling Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision criteria

Physical Examination

Tanner stage was determined by the same examiners at each visit and based on breast development in FtMs and testicular volume and genital development in MtFs.8, 9 Testicular volume was determined using a Prader orchidometer. Weight and height were measured using an electronic scale and a wall-mounted stadiometer (SECA, Hanover, MD, USA), with weight measured to the nearest 0.1 kg and height to the nearest 0.1 cm. Height SD score (SDS) was calculated using Dutch reference data¹⁰ and body mass

Anthropometry and Body Composition

Baseline characteristics are presented in Table 1. Height, weight, and BMI significantly increased during the first year of treatment in girls and boys. In MtFs, height SDS significantly decreased by 0.23 ± 0.23 in the first year of treatment (n = 36, P < .001), by 0.28 ± 0.14 in the second year (n = 21, P < .001), and did not change in the third year (n = 3). BMI SDS did not significantly change in the first year and increased by 0.13 ± 0.21 in the second year (n = 21, P = .009). In FtMs,

Discussion

Although GnRHa treatment has become the treatment of choice in gender dysphoric adolescents, few data are available on the efficacy and safety of this treatment in this population. Therefore, the Endocrine Society recommends rather extensive safety monitoring.³ We set out to evaluate the extent to which (early) pubertal physical changes can be reversed, the need for monitoring of gonadotropins and sex steroid levels, and the need for screening of liver and renal function.

Regression of early sex

Conclusions

We have shown that GnRHa treatment using triptorelin is effective in suppressing gonadotropins and sex steroids and results in a decrease in testicular volume and cessation of menstrual bleeding. Monitoring of creatinine and liver enzymes did not identify any pathology. Therefore, we propose that routinely monitoring gonadotropins, sex steroid levels, renal function, and liver enzymes during GnRHa treatment using triptorelin is not necessary. Further studies will have to determine the extent to

Statement of Authorship

Category 1

(a)
Conception and Design
- Peggy T. Cohen-Kettenis; Henriette A. Delemarre-van de Waal
(b)
Acquisition of Data
- Sebastian E.E. Schagen; Henriette A. Delemarre-van de Waal
(c)
Analysis and Interpretation of Data
- Sebastian E.E. Schagen; Sabine E. Hannema

Category 2

(a)
Drafting the Article
- Sabine E. Hannema
(b)
Revising It for Intellectual Content
- Sebastian E.E. Schagen; Peggy T. Cohen-Kettenis

Category 3

(a)
Final Approval of the Completed Article
- Sebastian E.E. Schagen; Peggy T. Cohen-Kettenis; Sabine E. Hannema

References (29)

M. Aitken et al.
Evidence for an altered sex ratio in clinic-referred adolescents with gender dysphoria
J Sex Med
(2015)
T.D. Steensma et al.
Gender identity development in adolescence
Horm Behav
(2013)
A.L. de Vries et al.
Puberty suppression in adolescents with gender identity disorder: a prospective follow-up study
J Sex Med
(2011)
K. Khatchadourian et al.
Clinical management of youth with gender dysphoria in Vancouver
J Pediatr
(2014)
D.A. Dumesic et al.
Pituitary desensitization to gonadotropin-releasing hormone increases abdominal adiposity in hyperandrogenic anovulatory women
Fertil Steril
(1998)
A.S. Staphorsius et al.
Puberty suppression and executive functioning: An fMRI-study in adolescents with gender dysphoria
Psychoneuroendocrinology
(2015)
W.C. Hembree et al.
Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline
J Clin Endocrinol Metab
(2009)
H.A. Delemarre-van de Waal et al.
Clinical management of gender identity disorder in adolescents: a protocol on psychological and paediatric endocrinology aspects
Eur J Endocrinol
(2006)
J.C. Carel et al.
Consensus statement on the use of gonadotropin-releasing hormone analogs in children
Pediatrics
(2009)
American Psychiatric Association
Diagnostic and statistical manual of mental disorders
(2000)

W.A. Marshall et al.

Growth and physiological development during adolescence

Annu Rev Med

(1968)

J.M. Tanner

Growth at adolescence

(1962)

Y. Schonbeck et al.

The world's tallest nation has stopped growing taller: the height of Dutch children from 1955 to 2009

Pediatr Res

(2013)

T.J. Cole et al.

Establishing a standard definition for child overweight and obesity worldwide: international survey

BMJ

(2000)

Cited by (98)

Fertility preservation in transfeminine adolescents using TESE at the time of Histrelin Acetate subcutaneous implant placement: A Case Series
2023, Journal of Pediatric Urology
Fertility preservation (FP) is an important aspect of the care of transgender patients in whom Gender Affirming Medical Treatment (GAT) may begin before puberty is completed. While there are overall few studies that can be used to guide conversations about long-term effects of GAT, there are concerns that GAT could negatively impact fertility. Prior studies have shown low utilization of FP in this population, with avoidance of delay in starting GAT cited as one of the most common reasons for foregoing FP. It is possible that strategies to mitigate delay in commencement of GAT can facilitate higher FP utilization, maintaining options for future family building.
To describe our institution's experience with Testicular Sperm Extraction (TESE) for FP and Histrelin Acetate (Supprelin) Subcutaneous Implantation for GAT commencement.
A retrospective review of transfeminine adolescents at our institution from 2010 to 2022 who underwent TESE for FP at the time of Supprelin placement for GAT (FP/SP). Outcomes of interest included successful sperm retrieval, age at first visit to our institution's Transgender Multispecialty Service Health clinic (GeMS), age at time of FP/SP, testicular volume, and Tanner stage at time of FP/SP, and age when GnRH agonist (GnRHa) therapy was prescribed. Testosterone, LH, FSH, and Inhibin B values prior to combination FP/SP were also obtained.
Ten patients from 2017 to 2022 underwent FP/SP after prescription of GnRHa based on Endocrine Society Guidelines. Successful sperm retrieval and storage was achieved in all patients. Median age at FP/SP was fourteen years 5.5 months (range 12y5m-16y8m). Median time from GnRHa prescription to FP/SP was two months (range 2–5 m). Mean testicular volume at time of FP/SP was 13.2 cc (SD 3.38 cc, range 8–17 cc), and median Tanner Stage was IV (range III-V). Average testosterone level was 301.60 (SD 173.04), LH 3.00 (SD 1.25), FSH 3.33 (SD 1.71), Inhibin B 208.50 (SD 87.44).
Performing TESE for FP is feasible for transgender youth undergoing Histrelin implant placement, leading to short delays in starting GAT. Testicular volume and endocrine markers can provide preoperative insight into likelihood of successful sperm retrieval during TESE, are needed to identify which patients will have successful sperm retrieval to ensure optimal counseling and informed decision making for providers, patients and families.
Gender-Affirming Medical Treatments
2023, Child and Adolescent Psychiatric Clinics of North America
A Longitudinal Study on Disordered Eating in Transgender and Nonbinary Adolescents
2023, Academic Pediatrics
We longitudinally explored frequency of disordered eating among transgender and nonbinary (TGNB) adolescents and explored trends by gender identity and gender-affirming care.
Participants completed an abbreviated version of the Eating Disorder Examination Questionnaire (EDE-Q) at baseline, 3, 6, and 12 months after establishing care in a gender clinic. We analyzed descriptive statistics and multivariate linear regression analyses.
Of the 91 TGNB adolescent participants, 61% were transmasculine, 30% transfeminine, and 7% nonbinary/gender-fluid. Among TGNB adolescents, disordered eating thoughts/behaviors were frequently endorsed with 26% of participants engaging in any occurrence of binge eating, 27% limiting the amount of food they ate, and 30% excluding foods from their diet. Forty percent of participants reported any occurrence of at least 1 disordered eating behavior and 17% at least 3 behaviors. Abbreviated EDE-Q responses did not differ significantly by sex assigned at birth, gender identity, gender-affirming medications, or time spent receiving gender-affirming care. There was a significant effect of age (P value = .003) on abbreviated EDE-Q scores.
There were no significant changes in disordered eating after initiating gender-affirming medical care, possibly due to the limited study time frame of 12 months. Given the high prevalence of disordered eating behaviors, clinicians should consider screening all TGNB adolescents for disordered eating thoughts/behaviors throughout gender-affirming care. Future longitudinal research should recruit larger samples with a diverse range of gender identities and survey disordered eating thoughts/behaviors at least one year after starting gender-affirming medications.
Physiological and pharmacological overview of the gonadotropin releasing hormone
2023, Biochemical Pharmacology
Gonadotropin-Releasing Hormone (GnRH) is a decapeptide responsible for the control of the reproductive functions. It shows C- and N-terminal aminoacid modifications and two other distinct isoforms have been so far identified. The biological effects of GnRH are mediated by binding to high-affinity G-protein couple receptors (GnRHR), showing characteristic very short C tail. In mammals, including humans, GnRH-producing neurons originate in the embryonic nasal compartment and during early embryogenesis they undergo rapid migration towards the hypothalamus; the increasing knowledge of such mechanisms improved diagnostic and therapeutic approaches to infertility. The pharmacological use of GnRH, or its synthetic peptide and non-peptide agonists or antagonists, provides a valid tool for reproductive disorders and assisted reproduction technology (ART).
The presence of GnRHR in several organs and tissues indicates additional functions of the peptide. The identification of a GnRH/GnRHR system in the human endometrium, ovary, and prostate has extended the functions of the peptide to the physiology and tumor transformation of such tissues. Likely, the activity of a GnRH/GnRHR system at the level of the hippocampus, as well as its decreased expression in mice brain aging, raised interest in its possible involvement in neurogenesis and neuronal functions. In conclusion, GnRH/GnRHR appears to be a fascinating biological system that exerts several possibly integrated pleiotropic actions in the complex control of reproductive functions, tumor growth, neurogenesis, and neuroprotection.
This review aims to provide an overview of the physiology of GnRH and the pharmacological applications of its synthetic analogs in the management of reproductive and non-reproductive diseases.
The effects of the gender transition on musculoskeletal health
2023, The Transgender Athlete: A Guide for Sports Medicine Providers
Gender transition and gender-affirming therapy (GAHT) often involve complex hormonal and structural changes which can have important implications for individuals involved in competitive and recreational sport. Although there is limited data pertaining specifically to transgender athletes, the effects of sex hormones on musculoskeletal structures and functional measures have been studied broadly. Although literature regarding the transgender population is somewhat limited, information may be gleaned from studies about other hormonal transition states including menstrual cycle, anabolic steroid use, menopause, aging, and various endocrine disorders and treatments.
Urological and Gynaecological Considerations for the Use of Gonadotropin-releasing Hormone Analogues in Transgender and Nonbinary Adolescents: A Narrative Review
2023, European Urology Focus
Citation Excerpt :
Specimens collected after cessation of GAH in 28 transgender women for an average of 4.4 mo were comparable to those from transgender women who had never used hormone medications [32]. The direct effects of GnRHAs on semen parameters in TGNB girls are not known, but testicular volume falls within 1 yr of GnRHA treatment [33]. Adult men who have completed their sexual maturation also demonstrated reversible suppression of spermatogenesis in studies of GnRHAs for male contraception (treated for up to 78 wk) [34] and for central precocious puberty [35].
Gonadotropin-releasing hormone analogues (GnRHAs) delay the progression of puberty in transgender and nonbinary (TGNB) adolescents and reduce the impact of dysphoria due to ongoing physical development. The intervention remains contentious despite growing evidence to support this practice.
To stimulate discussion on this topical issue in the urological and gynaecological community given potential ramifications for future fertility, physical development, and options for gender affirmation surgery (GAS).
We conducted searches of the MEDLINE (from 1946) and Embase (from 1974) databases for the benefits and potential challenges of hormone blockade in TGNB adolescents on February 1, 2022. Evidence with a primary focus on clinical issues of interest to urologists and gynaecologists was objectively synthesised and reported.
The onset of puberty represents a period of distress for TGNB adolescents as secondary sexual characteristics develop. GnRHAs are prescribed to inhibit sex hormone production, but the decision to treat should be balanced against the known (and unknown) adverse effects. Fertility preservation is more likely to be successful if GnRHA treatment is delayed for as long as possible. Some adolescents may decide to stop GnRHA use to harvest spermatozoa or oocytes before starting gender-affirming hormone treatment. Transfeminine individuals should consider that options for genital GAS may become more limited, as vaginoplasty with penile skin inversion requires an adequate stretched penile length. Transmasculine individuals may no longer require chest reconstruction for breast development.
Offers of GnRHA treatment to TGNB adolescents should be balanced by careful preparation and counselling. Urologists and gynaecologists can complement the expertise of specialist psychosocial and adolescent endocrinology teams, and should be involved early in and throughout the treatment pathway to maximise future functional and surgical outcomes.
Puberty blockers for transgender and nonbinary adolescents have benefits, but timing is important to preserve fertility and surgical options.

Original ResearchTransgender HealthEfficacy and Safety of Gonadotropin-Releasing Hormone Agonist Treatment to Suppress Puberty in Gender Dysphoric Adolescents

Abstract

Introduction

Aim

Methods

Main Outcome Measures

Results

Conclusion

Introduction

Section snippets

Aim

Subjects and Protocol

Physical Examination

Anthropometry and Body Composition

Discussion

Conclusions

Statement of Authorship

J Sex Med

Horm Behav

J Sex Med

J Pediatr

Fertil Steril

Psychoneuroendocrinology

Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline

J Clin Endocrinol Metab

Clinical management of gender identity disorder in adolescents: a protocol on psychological and paediatric endocrinology aspects

Eur J Endocrinol

Consensus statement on the use of gonadotropin-releasing hormone analogs in children

Pediatrics

Diagnostic and statistical manual of mental disorders

Growth and physiological development during adolescence

Annu Rev Med

Growth at adolescence

The world's tallest nation has stopped growing taller: the height of Dutch children from 1955 to 2009

Pediatr Res

Establishing a standard definition for child overweight and obesity worldwide: international survey

BMJ

Original Research
Transgender Health
Efficacy and Safety of Gonadotropin-Releasing Hormone Agonist Treatment to Suppress Puberty in Gender Dysphoric Adolescents